Hims Hers Health Inc Watch: Q1 FY2026 Earnings Prediction — Demand Strength Amid Regulatory Headwinds
Web traffic grew 15.5% QoQ in Jan–Mar 2026, signaling robust demand. I think FDA restrictions point to a slight revenue dip.
Intro Hook
Web traffic surged 15.5% QoQ to about 23.7 million visits, driven by strength in women’s health domains; that demand signal contrasts with a potential revenue dip from FDA restrictions on compounded weight loss drugs. The near-term print may disappoint given the recent run in the stock, but the setup here is materially different from where Hims was a few years ago.
The legal overhangs that weighed on the stock for years are largely resolved. The narrative has shifted cleanly to peptides, a category with what looks like durable demand ahead. That is a fundamentally better story to own, and the market is starting to price it that way without yet going completely off the rails on valuation. After years of trading at multiples that assumed perfection, Hims is now sitting at a valuation that looks grounded; not cheap in an absolute sense, but reasonable given the growth runway if the peptide category develops the way early signals suggest it will.
This is my first coverage post on HIMS, so errors are more likely than on names I have tracked for several quarters. The alt-data read will sharpen as I calibrate against reported results. That said, the stock has been on my radar for a long time and I have a view on the setup, which you can read in the editorial note above.
Outlook Snapshot
Q1 FY2026 covers Jan–Mar 2026. Last quarter, Q4 FY2025 (Oct–Dec 2025), revenue came in at USD 617.8M. Earnings are expected around 2026-05-11, per the EODHD calendar; Hims Hers Health Inc has not yet officially confirmed the day.
App Downloads Signal
App installs decelerated this quarter. iOS downloads, which make up 74% of the mix and often convert to higher-value subscribers, peaked in January before dropping in February and stabilizing in March; Android showed stability with a slight increase from January to February before holding steady. This softening in acquisition could pressure subscriber growth if conversion rates don’t hold up. The trend contrasts with web traffic strength, adding uncertainty to the revenue picture.
Web Traffic Signal
Aggregate web traffic rose 15.5% QoQ and 65.4% YoY, reaching about 23.7 million visits. Demand accelerated across the platform. The surge came largely from Hers-related domains. Forhers.com jumped sharply from 8.8 million to 11.6 million visits.
Apostrophe.com rebounded modestly to 20,675 visits after prior declines. Hims domains stayed mostly stable. Consistent traction held in men’s health.
Traffic drives user funnels into consultations and subscriptions. The uptick helps but may not fully offset disruptions elsewhere.
Intra-quarter patterns decelerated toward March. Momentum faded. Demand is positive overall, especially in women’s offerings.
Hers Brand Read
Signal sources: forhers.com, hers.com
Hers domains drove the quarter’s traffic growth. Forhers.com jumped sharply QoQ, while apostrophe.com rebounded slightly after declines. Traction strengthened in women’s health and skincare.
Engagement is the clearest signal in the Hers brand this quarter.
Hims Brand
Signal sources: hims.com, forhims.com, forhims.co.uk
Traffic for Hims domains held largely stable QoQ. Hims.com ticked up slightly, but forhims.com dipped modestly; the UK site stayed steady. Demand stayed consistent in men’s health without big shifts.
Engagement in the Hims brand is flat rather than accelerating this quarter.
Revenue Estimate
My Q1 FY2026 revenue estimate is USD 614.9M. The slight dip starts from last quarter’s USD 617.8M. The dip comes from decelerating app installs and intra-quarter traffic softening, despite the overall web uptick. Hers brand contributes positively with its traffic surge.
That adds growth in women’s health. Hims brand is stable, holding its ground without acceleration. Positive drivers include underlying revenue momentum and daily app trends. Monthly app deceleration weighs in.
Sensitivities sit around the FDA restrictions from February 2026, which halted compounded semaglutide sales—a segment worth $180-200M quarterly—but my estimate sticks to what the alt-data signals, treating the event as background risk rather than a direct adjustment. My estimate lands 0.4% below consensus, a minor divergence at medium confidence.
What the Market Thinks
Consensus from EODHD has revenue at USD 617.2M for Q1 FY2026, based on 12 analysts, with a band from USD 608.4M to USD 632.5M. EPS sits at 0.0383. The stock fell 37.9% over the quarter, from 33.41 to 20.76.
Market chatter focuses on regulatory risks, with positive sentiment around a scheduled FDA review of peptide compounding eligibility. Discussions highlight subscriber growth and the lab testing launch. Regulatory concerns caused volatility. The narrative emphasizes evolving into a scalable consumer health platform.
Risk Factors
My biggest worry is prolonged FDA restrictions from February 2026 halting compounded semaglutide, eroding the $180-200M quarterly from weight loss; if no offsets emerge, revenue could drop by up to 32%, pushing below USD 420M. App install deceleration adds pressure on subscriber adds, particularly on iOS where the monthly trend is softest. Signals are noisy here, so confidence is medium; actuals could diverge if intra-quarter trends worsen.
Traffic-Revenue Decoupling
Web traffic surged 15.5% QoQ to 23.7M visits, driven by Hers domains, but this demand strength contrasts with a potential revenue dip from FDA restrictions halting $180-200M in quarterly weight loss sales.
Weight Loss Segment Headwind
If the FDA crackdown on compounded semaglutide fully erodes the $180-200M quarterly from weight loss without offset from other segments, my revenue estimate could fall by up to 32%, landing below USD 420M.
Editorial Note
I have followed Hims for a while and traded it several times over the years, both short and long, with good results. The stock had significant legal overhangs and was trading at extended valuations a few years back; that setup is largely behind us now. The focus has shifted to peptides, a category I expect to see sustained demand in going forward.
For this quarter specifically, the setup looks different from prior periods. Revenue will likely print in a fairly expected range, and given the recent stock surge, a slightly soft print could trigger a modest dip. That is the near-term read.
Longer term I am more constructive. The peptide narrative will drive retail interest hard, and the valuation is looking grounded relative to where this stock has traded historically. Hims tends to swing to extremes; I would not be surprised to see it hit new all-time highs as retail momentum builds again. I will be tracking it closely.
Disclaimer: This research is informational and not personalized investment advice. Outputs blend alternative data with a disciplined internal workflow; figures are directional and may change as new information arrives. Past accuracy does not guarantee future results.
If you want more of these before they hit earnings, subscribe at emilhartela.com.